Compare · POCI vs TMDX
POCI vs TMDX
Side-by-side comparison of Precision Optics Corporation Inc. (POCI) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POCI and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.65B, about 55.6x POCI ($47.7M).
- POCI has been more active in the news (6 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (20 ratings vs 0 for POCI).
- Company
- Precision Optics Corporation Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $47.7M
- $2.65B
- 1M return
- +1.18%
- -
- 1Y return
- +2.38%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 2
- Recent ratings
- 0
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest POCI
- Amendment: SEC Form 4/A filed by Precision Optics Corporation Inc.
- Chief Financial Officer Coll Wayne M was granted 6,250 shares, increasing direct ownership by 16% to 46,218 units (SEC Form 4)
- Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference
- Precision Optics Corporation Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results
- SEC Form 10-K filed by Precision Optics Corporation Inc.
- Chief Operating Officer Traut Joseph was granted 6,742 shares, increasing direct ownership by 16% to 48,408 units (SEC Form 4)
- Chief Executive Officer Forkey Joseph Norman was granted 6,742 shares, increasing direct ownership by 5% to 150,701 units (SEC Form 4)
- Chief Financial Officer Coll Wayne M was granted 6,742 shares, increasing direct ownership by 18% to 44,806 units (SEC Form 4)
- Precision Optics Schedules Fourth Quarter and Fiscal Year 2026 Conference Call for September 28, 2026
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results